Christine M. Lovly, MD, PhD, FASCO
Articles
May 5th 2025
Lorlatinib in Focus: Survival, Brain Metastases, and Beyond
Ryan Haumschild, PharmD, MS, MBA, CPEL Elizabeth Castronovo, NP Martin Dietrich, MD, PhD Mary Grizzard, MSN, FNP Christine M. Lovly, MD, PhD, FASCO
Panelists discuss how the 5-year CROWN trial data for lorlatinib have shaped the treatment paradigm for ALK+ metastatic non-small cell lung cancer (NSCLC), particularly regarding long-term survival, durability of response, and management of brain metastases.
May 5th 2025
The Evolution of ALK+ NSCLC Care
Ryan Haumschild, PharmD, MS, MBA, CPEL Elizabeth Castronovo, NP Martin Dietrich, MD, PhD Mary Grizzard, MSN, FNP Christine M. Lovly, MD, PhD, FASCO
Panelists discuss how they will explore optimizing care for patients with ALK-positive non-small cell lung cancer (ALK+ NSCLC) through treatment selection, sequencing strategies, and interpretation of emerging clinical data.
Latest Updated Articles
Published: February 20th 2025 | Updated: February 21st 2025
Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP
Published: January 16th 2025 | Updated: January 29th 2025
FDA Proposal Aims to Reduce Smoking Addiction and SCLC Cases
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
